These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23015747)

  • 1. Ethics and eplerenone.
    Gupta S; Fugh-Berman AJ; Scialli A
    J Med Ethics; 2013 Feb; 39(2):110-4. PubMed ID: 23015747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eplerenone is not superior to older and less expensive aldosterone antagonists.
    Chatterjee S; Moeller C; Shah N; Bolorunduro O; Lichstein E; Moskovits N; Mukherjee D
    Am J Med; 2012 Aug; 125(8):817-25. PubMed ID: 22840667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G; Solesse A; Beillat M
    Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does eplerenone have a future in the management of hypertension in Europe?
    Gosse P; Macfadyen RJ
    J Hum Hypertens; 2006 Nov; 20(11):829-32. PubMed ID: 16915301
    [No Abstract]   [Full Text] [Related]  

  • 6. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of eplerenone in patients with chronic heart failure.
    Ademi Z; Pasupathi K; Krum H; Liew D
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):209-16. PubMed ID: 24610254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct; 146(43):58-9. PubMed ID: 15559524
    [No Abstract]   [Full Text] [Related]  

  • 10. Eplerenone after myocardial infarction?
    Drug Ther Bull; 2008 Jan; 46(1):1-3. PubMed ID: 18171726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study].
    Watanabe J
    Nihon Rinsho; 2007 Apr; 65 Suppl 4():543-6. PubMed ID: 17508588
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
    Ademi Z; Pasupathi K; Liew D
    Medicine (Baltimore); 2016 May; 95(18):e3531. PubMed ID: 27149456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of spironolactone in patients with severe heart failure.
    Tilson L; McGowan B; Ryan M; Barry M
    Ir J Med Sci; 2003; 172(2):70-2. PubMed ID: 12930056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.
    Ajani AE; Marwick TH; Krum H
    Cardiovasc Revasc Med; 2006; 7(4):234-6. PubMed ID: 17174870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
    Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone (GD Searle & Co).
    Martin J; Krum H
    Curr Opin Investig Drugs; 2001 Apr; 2(4):521-4. PubMed ID: 11566010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
    Kalidindi SR; Tang WH; Francis GS
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
    Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.